PGM
STLN

Parian Global Management’s Starling Oncology STLN Stock Holding History

Parian Global Management’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.11M Buy
240,724
+56,896
+31% +$335K 3.63% 9
2022
Q2 		$930K Sell
183,828
-260,416
-59% -$1.9M 4.26% 11
2022
Q1 		$3.17M Sell
444,244
-22,432
-5% -$151K 6.53% 6
2021
Q4 		$4.55M Buy
+466,676
New +$4.15M 3.65% 9

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parian Global Management's STLN Position: Q3 2022 in Review

Parian Global Management increased its Starling Oncology (STLN) stake by 31% in Q3 2022, buying an estimated $335K and bringing the position to 240,724 shares worth $1.11M. The position accounts for 3.63% of the portfolio, ranked #9.

Parian Global Management first reported a position in STLN in Q4 2021 and has held it in 4 quarters since. The position peaked at $4.55M in Q4 2021. 39 funds tracked by Wall St. Rank hold STLN as of Q3 2022.

  • Parian Global Management held 240,724 shares of Starling Oncology worth $1.11M as of Q3 2022.
  • Parian Global Management bought 56,896 Starling Oncology shares in Q3 2022, an estimated $335K.
  • Starling Oncology made up 3.63% of Parian Global Management's portfolio in Q3 2022, its #9 holding.
  • Parian Global Management first reported a position in Starling Oncology in Q4 2021 and has held it in 4 quarters since.
  • Parian Global Management's Starling Oncology position peaked at $4.55M in Q4 2021.
  • 39 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2022.

Based on Parian Global Management's 13F filing for Q3 2022, filed 14 Nov 2022.